Weatherly Asset Management L. P. Sells 192 Shares of DexCom, Inc. (NASDAQ:DXCM)

Weatherly Asset Management L. P. trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,618 shares of the medical device company’s stock after selling 192 shares during the quarter. Weatherly Asset Management L. P.’s holdings in DexCom were worth $2,807,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Valley National Advisers Inc. increased its holdings in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the period. MV Capital Management Inc. increased its holdings in DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares during the period. Washington Trust Advisors Inc. increased its holdings in DexCom by 120.6% in the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after buying an additional 193 shares during the period. Turtle Creek Wealth Advisors LLC bought a new position in DexCom in the 4th quarter valued at about $57,000. Finally, NBC Securities Inc. bought a new position in DexCom in the 3rd quarter valued at about $47,000. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

DXCM has been the topic of a number of research analyst reports. UBS Group raised their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Raymond James raised their price target on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 23rd. Citigroup raised their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada initiated coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $141.40.

DexCom Trading Up 1.9 %

Shares of NASDAQ DXCM traded up $2.48 during midday trading on Tuesday, reaching $134.00. The stock had a trading volume of 2,014,507 shares, compared to its average volume of 2,958,850. The firm has a market cap of $51.66 billion, a price-to-earnings ratio of 100.40, a price-to-earnings-growth ratio of 2.25 and a beta of 1.20. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. The company’s 50 day moving average price is $129.81 and its 200 day moving average price is $117.38.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The company’s revenue for the quarter was up 26.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.34 EPS. As a group, sell-side analysts expect that DexCom, Inc. will post 1.76 EPS for the current year.

Insider Transactions at DexCom

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the transaction, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Jereme M. Sylvain sold 3,363 shares of DexCom stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the sale, the executive vice president now owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 189,375 shares of company stock worth $25,530,859. Company insiders own 0.41% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.